TFS HealthScience will support Oncomatryx's Phase Ib clinical trial of OMTX705, a novel antibody-drug conjugate targeting fibroblast activation protein, in patients with advanced or metastatic pancreatic adenocarcinoma.
Oncomatryx has successfully raised €25 million to fund Phase Ib-II clinical trials of OMTX705, a first-in-class antibody-drug conjugate (ADC) targeting Fibroblast Activation Protein (FAP).
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.